By David Wallace | September 13, 2026 The FDA approved BESREMi for essential thrombocythemia on August 31, 2026, giving adults with ET their first new FDA-approved treatment in nearly 30 years. BESREMi (ropeginterferon alfa-2b-njft) is a long-acting interferon given by injection every two weeks. If hydroxyurea is not controlling your disease or its side effects […]
SURPASS-ET: Earlier Ropeginterferon Shows 2-Year Benefit
by David Wallace September 1, 2026 Update Big news for the ET community: The FDA has approved BESREMi® for adults with essential thrombocythemia (ET). Stay tuned for our detailed article explaining what this approval could mean for patients. Two-year results from the Phase 3 SURPASS-ET trial suggest that earlier initiation of ropeginterferon alfa-2b may provide […]
From Questions to Confidence: Piecing Together the Facts About Essential Thrombocythemia
Sponsored Post Being diagnosed with a rare, chronic blood cancer like essential thrombocythemia, or ET, can feel overwhelming and isolating. In the United States, approximately 24 out of every 100,000 people are currently living with ET. Because ET is uncommon, it may be hard to know where to turn for clear, trustworthy information—especially early in […]
Michael’s MPN Story
by Michael Movsky My MPN journey began at the hematologist’s office on a pleasant March day in 2018, when she confirmed a diagnosis of Essential Thrombocytosis (ET) through various factors, including the detection of the JAK 2 mutation…at which point I was handed an informational booklet on the topic from the Leukemia and Lymphoma Society. […]
